Brainsway Shares Rally Premarket on FDA OK of Deep TMS H7 Coil to Treat Depression
29 8월 2022 - 9:56PM
Dow Jones News
By Colin Kellaher
Shares of Brainsway Ltd. jumped more than 20% in premarket
trading Monday after the maker of noninvasive neurostimulation
treatments said it received Food and Drug Administration approval
for the expanded use of its Deep TMS H7 coil for depression in
adults.
The Jerusalem company said the approval covers adults with major
depressive disorder and depression, including those with comorbid
anxiety symptoms commonly known as anxious depression.
The H7 coil has been approved to treat obsessive-compulsive
disorder since 2018.
Brainsway shares, which closed Friday at $4.50, were recently up
nearly 22% to $5.47 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 29, 2022 08:41 ET (12:41 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Brainsway (NASDAQ:BWAY)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Brainsway (NASDAQ:BWAY)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
